Is Dose-Dense Therapy Effective Against DLBCL in the Era of Rituximab? Cancer Network The authors asked whether there is still debate surrounding dose intensity since the introduction of the monoclonal antibody rituximab (Rituxan [R]), which has improved the clinical outcomes of patients with DLBCL. The focus of the review addressed the ... |
